文献速递淋巴瘤

滤泡性淋巴瘤的终点与结局:应测量什么、如何测量及为何测量

End points and outcomes in follicular lymphoma: what should we measure, how, and why?
PubMed 文献 · Blood · 2025-01-01

综述讨论滤泡性淋巴瘤(FL)试验中常用终点的优势与局限,指出中位总生存(OS)接近20年使OS难以作为主要终点。作者认为充分验证的替代终点如启动一线免疫化疗后30个月完全缓解可用于确证性随机试验的主要或共同主要终点,微小残留病等新兴中间终点可用于早期试验和加速审批,并应将生活质量(QoL)和非医疗负担作为重要次要终点。

要点

  • FL患者中位OS接近20年,OS作为主要终点常不可行
  • 启动一线免疫化疗后30个月完全缓解等验证替代终点可用于确证性随机试验主要或共同主要终点
  • 微小残留病等新兴中间终点可用于早期试验和加速审批,生活质量应作为重要次要终点

核心结论

  • 临床相关、及时且以患者为中心的终点可能识别帮助FL患者活得更长更好的新药。

研究设计与样本

  • 综述,讨论FL试验中常用传统终点的优势与局限及当前差距。

主要发现

  • FL患者中位OS接近20年,使OS作为临床研究主要终点常不可行。
  • 淋巴瘤患者已有验证工具评估QoL,但QoL数据很少作为FL药物批准的唯一依据。
  • 当前终点存在结果延迟可用性和区分治疗效应差异敏感性欠佳等差距。

关键数值与推荐

  • 启动一线免疫化疗后30个月完全缓解等充分验证的替代终点可作为确证性随机试验的主要或共同主要终点。
  • 微小残留病等新兴中间终点经适当验证后可用于早期试验和指导加速审批。
  • QoL应作为重要次要试验终点,并测量包括时间和财务毒性在内的非医疗负担。

临床怎么用

  • 作者认为充分验证的替代终点如启动一线免疫化疗后30个月完全缓解可作为确证性随机试验的主要或共同主要终点。
  • 作者认为微小残留病等新兴中间终点可用于早期试验和指导加速审批。
  • 作者认为应将QoL作为重要次要终点并测量非医疗负担。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Overall survival (OS) and quality of life (QoL) are clinically relevant outcomes/end points during examination of therapies. However, with median OS approaching 20 years for patients with follicular lymphoma (FL), it is often not feasible to use OS as a primary end point in clinical studies. Although validated tools exist for assessing QoL in patients with lymphoma, QoL data are rarely the sole basis for drug approvals in FL. Therefore, other survival end points, surrogates, and intermediate clinical end points have all been used to measure outcomes in FL trials. In this review, we discuss the strengths and limitations of these commonly used traditional end points in FL trials and examine the current gaps, including delayed availability of results and suboptimal sensitivity in distinguishing difference in therapeutic effects. To help address the identified gaps, well-validated surrogates, such as complete remission 30 months after starting frontline immunochemotherapy, may be used as the primary or co-primary end point in confirmatory randomized trials. Emerging intermediate end points like minimal residual disease may be useful in early phase trials and in guiding accelerated approvals after appropriate validation. As patient preference plays a crucial role in treatment decisions in FL, it is critical to include QoL as an important secondary trial end point and to measure nonmedical burdens, including time and financial toxicities. End points that are clinically relevant, timely, and patient-centered may identify new drugs that help patients with FL live longer and better lives.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Di M, Maurer MJ, Flowers CR, et al. End points and outcomes in follicular lymphoma: what should we measure, how, and why? Blood. 2025. PMID: 40019453. doi:10.1182/blood.2024026978

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。